Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1

Interventions

Rituximab 24Cyclophosphamide 20fludarabine phosphate 16Mycophenolic Acid 13Filgrastim 12Cyclosporine 12Bortezomib 12Antilymphocyte Serum 11Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Lenalidomide 9fludarabine 8Radiotherapy 7Methotrexate 7Cord Blood Stem Cell Transplantation 7Melphalan 6Busulfan 6venetoclax 5Etoposide 5tanespimycin 4ibrutinib 4Polymerase Chain Reaction 4Methylprednisolone 4Granulocyte Colony-Stimulating Factor 4Flow Cytometry 4ublituximab 3thymoglobulin 3sargramostim 3carfilzomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Mantle-Cell × MLN2238 × Clear all
NCT04047797 2025-04-20

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡